ASHEcon 2024: The Annual Conference of the American Society of Health Economists
Cornerstone Research staff and affiliated experts will speak at this annual conference hosted by the American Society of Health Economics.
2024 Antitrust in Healthcare
James Lee of Cornerstone Research will discuss competition issues in healthcare and life sciences at this American Bar Association conference.
Entrenching and Leveraging Market Dominance in the 2023 Merger Guidelines: Insights from Amgen/Horizon
Insights from Amgen/Horizon merger on leveraging market dominance via bundling under 2023 Merger Guidelines.
How A 3-Firm ‘Joint Effort’ Beat A $3.6B Pharma Antitrust Suit
In this Law360 article, counsel discusses Celeste Saravia’s pivotal role as the economic expert in a pharmaceutical antitrust lawsuit.
Ciccio et al. v. SmileDirectClub LLC et al.
Class certification was denied in this false advertising matter.
5 Questions with Sayeh Nikpay: The 340B Drug Pricing Program
Professor Sayeh Nikpay of the University of Minnesota discusses the role and implementation challenges of the 340B Drug Pricing Program.
Most-Favored Entry Clauses in Drug-Patent Litigation Settlements
The authors examine the competitive impacts of such clauses taking into account the regulatory structure and economics of the pharmaceutical industry in the United States.
Q&A with Joanna Tsai
WWL interviewed Joanna Tsai of Cornerstone Research about working at the FTC, the evolution of merger analysis, and her advice for aspiring competition economists.
The Inflation Reduction Act’s Effects on the Life Sciences Industry
Our industry experts break down the IRA’s impact on life sciences, highlighting critical shifts in drug pricing strategy, R&D allocation, and commercialization models.
The Global Antitrust Economics Conference 2023
Rainer Schwabe and Anand Krishnamurthy will join competition experts to discuss the role of financial services and life sciences in antitrust.
Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.
Laurence Baker testified during a rare antitrust trial centering on the allegation that a brand manufacturer conspired with three generics to allocate the market for gout medication colchicine.
In re Novartis and Par Antitrust Litigation
Novartis reached settlements with plaintiffs in this reverse payment matter.
How can we help you?
If you are looking for a publication not on our website, contact us.